MDMA, methamphetamine, and CYP2D6 pharmacogenetics: What is clinically relevant?

Frontiers in Genetics

Volumn 3, Issue NOV, 2012, Pages

  de la Torre, Rafael ^a,b   Yubero Lahoz, Samanta ^a,b   Pardo Lozano, Ricardo ^a,c   Farré, Magí ^a,c  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

CYP2D6; Ecstasy; MDMA; Methamphetamine; Pharmacogenetics

Indexed keywords

EID: 84876197532     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00235     Document Type: Review

References (56)

1. Aitchison, K. J., Tsapakis, E. M., Huezo-Diaz, P., Kerwin, R. W., Forsling, M. L., and Wolff, K. (2012). Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. J. Psychopharmacol. 26, 408-41
2. Bach, M. V., Coutts, R. T., and Baker, G. B. (1999). Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two Nalkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 29, 719-73
3. Bogni, A., Monshouwer, M., Moscone, A., Hidestrand, M., Ingelman-Sundberg, M., Hartung, T., et al. (2005). Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol In Vitro 19, 621-62
4. Bousman, C. A., Glatt, S. J., Everall, I. P., and Tsuang, M. T. (2009). Genetic association studies of methamphetamine use disorders: a systematic review and synthesis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B, 1025-104
5. Cherner, M., Bousman, C., Everall, I., Barron, D., Letendre, S., Vaida, F., et al. (2010). Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine- associated neurocognitive impairment: preliminary findings. J. Int. Neuropsychol Soc. 16, 890-90
6. Cook, C. E., Jeffcoat, A. R., Hill, J. M., Pugh, D. E., Patetta, P. K., Sadler, B. M., et al. (1993). Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab. Dispos. 21, 717-72
7. Delaforge, M., Jaouen, M., and Bouille, G. (1999). Inhibitory metabolite complex formation of methylene-dioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D. Environ. Toxicol. Pharmacol. 7, 153-15
8. de la Torre, R., and Farré, M. (2004). Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol. Sci. 25, 505-50
9. de la Torre, R., Farré, M., Mathúna, B. O., Roset, P. N., Pizarro, N., Segura, M., et al. (2005). MDMA (ecstasy) pharmacokinetics in aCYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur. J. Clin. Pharmacol. 61, 551-55
10. de la Torre, R., Farré, M., Ortuño, J., Mas, M., Brenneisen, R., Roset, P. N., et al. (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol. 49, 104-10
11. de la Torre, R., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., et al. (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 26, 137-14
12. de la Torre, R., Ortuño, J., Mas, M., Farré, M., and Segura, J. (1999). Fatal MDMA intoxication. Lancet 353,59
13. Farré, M., Abanades, S., Roset, P. N., Peiró, A. M., Torrens, M., O'Mathúna, B., et al. (2007). Pharmacological interaction between 3, 4- methylenedioxymeth amphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J. Pharmacol. Exp. Ther. 323, 954-96
14. Farré, M., de la Torre, R., Mathúna, B. O., Roset, P. N., Peiró, A. M., Torrens, M., et al. (2004). Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl.) 173, 364-37
15. Gilhooly, T. C., and Daly, A. K. (2002). CYP2D6 deficiency, a factor in ecstasy related deaths? Br. J. Clin. Pharmacol. 54, 69-7
16. Green, A. R., Mechan, A. O., Elliott, J. M., O'Shea, E., and Colado, M. I. (2003). The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55, 463-50
17. Hales, G., Roth, N., and Smith, D. (2000). Possible fatal interaction between protease inhibitors and methamphetamine. Antivir. Ther. 5, 1
18. Henry, J. A., and Hill, I. R. (1998). Fatal interaction between riton-avir and MDMA. Lancet 352, 1751-175
19. Henry, J. A., Jeffreys, K. J., and Dawling, S. (1992). Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340, 384-38
20. Heydari, A., Yeo, K. R., Lennard, M. S., Ellis, S. W., Tucker, G. T., and Rostami-Hodjegan, A. (2004). Mechanism-based inactivation of CYP2D6 by methylenedioxy methamphetamine. Drug Metab. Dispos. 32, 1213-121
21. Hysek, C. M., Simmler, L. D., Ineichen, M., Grouzmann, E., Hoener, M. C., Brenneisen, R., et al. (2011). The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Clin. Pharmacol. Ther. 90, 246-25
22. Hysek, C. M., Simmler, L. D., Nicola, V. G., Vischer, N., Donzelli, M., Krähenbühl, S., et al. (2012). Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE 7:e36476. doi: 10.1371/journal.pone.0036476
23. Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-1
24. Jones, D. C., Duvauchelle, C., Ikegami, A., Olsen, C. M., Lau, S. S., de la Torre, R., et al. (2005). Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.J. Pharmacol. Exp. Ther. 313, 422-43
25. Kreth, K., Kovar, K., Schwab, M., and Zanger, U. M. (2000). Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem. Pharmacol. 59, 1563-157
26. Lin, L. Y., Di Stefano, E. W., Schmitz, D. A., Hsu, L., Ellis, S. W., Lennard, M. S., et al. (1997). Oxidation of methamphetamine and methylene- dioxymethamphetamine by CYP2D6. Drug Metab. Dispos. 25, 1059-106
27. Liston, H. L., DeVane, C. L., Boulton, D. W., Risch, S. C., Markowitz, J. S., and Goldman, J. (2002). Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J. Clin. Psychopharmacol. 22, 169-17
28. Matsusue, A., Hara, K., Kashiwagi, M., Kageura, M., Sugimura, T., and Kubo, S. (2011). Genetic analysis of the rhabdomyolysis-associated genes in forensic autopsy cases of methamphetamine abusers. Leg. Med. (Tokyo) 13, 7-1
29. Meyer, M. R., Peters, F. T., and Maurer, H. H. (2009a). Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. Toxicol Lett. 190, 54-6
30. Meyer, M. R., Peters, F. T., and Maurer, H. H. (2009b). Stereoselective differences in the cytochrome P450 dependent dealkylation and demethylenation of N- methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. Biochem. Pharmacol 77, 1725-173
31. Newton, T. F., Roache, J. D., De La Garza, R. 2nd., Fong, T., Wallace, C. L., Li, S. H., et al. (2005). Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl.) 182, 426-43
32. Newton, T. F., Roache, J. D., De La Garza, R. 2nd., Fong, T., Wallace, C. L., Li, S. H., et al. (2006). Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 31, 1537-154
33. O'Donohoe, A., O'Flynn, K., Shields, K., Hawi, Z., and Gill, M. (1998). MDMA toxicity. No evidence for a major influence of metabolic genotype at CYP2D6. Addict. Biol. 3, 309-31
34. O'Mathúna, B., Farré, M., Rostami-Hodjegan, A., Yang, J., Cuyàs, E., Torrens, M., et al. (2008). The consequences of 3, 4-methylenedioxymeth amphetamine induced CYP2D6 inhibition in humans. J. Clin. Psychopharmacol. 28, 523-52
35. Otani, K., Ujike, H., Sakai, A., Okahisa, Y., Kotaka, T., Inada, T., et al. (2008). Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neurosci. Lett. 434, 88-9
36. Papaseit, E., Vázquez, A., Pérez-Mañá, C., Pujadas, M., de la Torre, R., Farré, M., et al. (2012). Surviving life-threatening MDMA (3, 4-methylenedioxy methamphetamine, ecstasy) toxicity caused by ritonavir (RTV). Intensive Care Med. 38, 1239-124
37. Perfetti, X., O'Mathúna, B., Pizarro, N., Cuyàs, E., Khymenets, O., Almeida, B., et al. (2009). Neurotoxic thioether adducts of 3, 4-methylenedioxymeth amphetamine identified in human urine after ecstasy ingestion. Drug Metab. Dispos. 37, 1448-145
38. Ramamoorthy, Y., Tyndale, R. F., and Sellers, E. M. (2001). Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11, 477-48
39. Sachse, C., Brockmöller, J., Bauer, S., and Roots, I. (1997). Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-29
40. Schep, L. J., Slaughter, R. J., and Beasley, D. M. (2010). The clinical toxicology of metamfe-tamine. Clin. Toxicol. (Phila.). 48, 675-69
41. Schwab, M., Seyringer, E., Brauer, R. B., Hellinger, A., and Griese, E.U. (1999). Fatal MDMA intoxication. Lancet 353, 593-59
42. Segura, M., Farré, M., Pichini, S., Peiró, A. M., Roset, P. N., Ramírez, A., et al. (2005). Contribution of cytochrome P450 2D6 to 3, 4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin. Pharmacokinet. 44, 649-66
43. Sellers, E. M., and Tyndale, R. F. (2000). Mimicking gene defects to treat drug dependence. Ann. N.Y.Acad. Sci. 909, 233-24
44. Shima, N., Tsutsumi, H., Kamata, T., Nishikawa, M., Katagi, M., Miki, A., et al. (2006). Direct determination of glucuronide and sulfate of p-hydroxymethamphetamine in methamphetamine users' urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830, 64-7
45. Springer, D., Fritschi, G., and Maurer, H. H. (2003a). Metabolism and toxicological detection of the new designer drug 3′, 4′-methylenedioxy-alpha- pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 793, 377-38
46. Springer, D., Fritschi, G., and Maurer, H. H. (2003b). Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796, 253-26
47. Springer, D., Staack, R. F., Paul, L. D., Kraemer, T., and Maurer, H. H. (2003c). Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica 33, 989-99
48. Staack, R. F., Theobald, D. S., Paul, L. D., Springer, D., Kraemer, T., and Maurer, H. H. (2004). Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine. Drug Metab. Dispos. 32, 379-38
49. Tucker, G. T., Lennard, M. S., Ellis, S. W., Woods, H. F., Cho, A. K., Lin, L. Y., et al. (1994). The demethylenation of methylene-dioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 47, 1151-115
50. UNODC (United Nations Office obn Drugs and Crime). (2011). 2011 Global ATS Assessment available online at: http://www.unodc.org/documents/ATS/ATS_Global_Assessment_2011.pdf.
51. Wolff, K., Tsapakis, E. M., Pariante, C. M., Kerwin, R. W., Forsling, M. L., and Aitchison, K. J. (2012). Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. J. Psychopharmacol. 26, 419-42
52. Wu, D., Otton, S. V., Inaba, T., Kalow, W., and Sellers, E. M. (1997). Interactions of amphetamine analogs with human liver CYP2D6. Biochem. Pharmacol. 53,1605-161
53. Yang, J., Jamei, M., Heydari, A., Yeo, K. R., de la Torre, R., Farré, M., et al. (2006). Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J. Psychopharmacol. 20, 842-84
54. Yubero-Lahoz, S., Pardo, R., Farre, M., Mathuna, B. O., Torrens, M., Mustata, C., et al. (2012). Changes in CYP1A2 activity in humans after 3, 4-methylenedioxymeth amphetamine (MDMA, Ecstasy) administration using caffeine as probe drug. Drug Metab. Pharmacokinet. 27, 1-9.
55. Yubero-Lahoz, S., Pardo, R., Farré, M., O'Mahony, B., Torrens, M., Mustata, C., et al. (2011). Sex differences in 3, 4- methylenedioxymeth amphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin. Pharmacokinet. 50, 319-32
56. Zanger, U. M., Raimundo, S., and Eichelbaum, M. (2004). Cytochrome P450 2D6, overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-3